লোডিং…
Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme
BACKGROUND: The gefitinib compassionate-use programme has enabled >39,000 patients worldwide to receive gefitinib ('Iressa', ZD1839) treatment. This paper reports the outcome of gefitinib treatment in Chinese patients who enrolled into the 'Iressa' Expanded Access Programme (E...
| প্রধান লেখক: | , , , , |
|---|---|
| বিন্যাস: | পাঠ্য |
| ভাষা: | English |
| প্রকাশিত: |
BioMed Central
2004
|
| বিষয়গুলি: | |
| অনলাইন ব্যবহার করুন: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC516034/ https://www.ncbi.nlm.nih.gov/pubmed/15318946 http://dx.doi.org/10.1186/1471-2407-4-51 |